Abstract
Treatment of locally advanced non-small cell lung cancer (NSCLC) remains a significant challenge for oncologists, despite progress made in recent years in early diagnosis and therapy. This review focuses on integrated therapeutic approaches of patients with locally advanced NSCLC, summarizing the available evidence for patients with potentially resectable disease (stage IIIA-0/3) and with unresectable disease (stage IIIA-4/IIIB) and discussing several key questions related to the use of integrated approaches in NSCLC. Based on current evidence, neoadjuvant platinum-based combination chemotherapy is a treatment option in patients with potentially resectable stage IIIA-0/3: a 2-drug combination of platinum combined with a third-generation drug seems preferable, and at least 3 cycles of chemotherapy should be administered. There are no definitive evidences of clear superiority of surgery compared to radiotherapy for patients obtaining a response with neoadjuvant treatment: however, surgery is associated with a better local control, and subgroup analyses of randomized trials suggest improved outcome in patients in whom a complete resection could be obtained with a lobectomy, avoiding the increased surgical mortality associated with pneumonectomy. Standard treatment for patients with locally advanced, unresectable NSCLC is currently represented by combination of chemotherapy and radiotherapy. Concomitant approach has been proven superior to the sequential administration, although it is associated with higher risk of toxicity. All patients should be evaluated by a multidisciplinary team, skilled in multimodality treatment and should be counselled about risks and potential benefits of the different therapeutic approaches.
Keywords: Locally advanced NSCLC, multidisciplinary approach, combined treatment, chemotherapy, radiotherapy, surgery.
Anti-Cancer Agents in Medicinal Chemistry
Title:Integrated Therapeutic Approaches in the Treatment of Locally Advanced Non-small Cell Lung Cancer
Volume: 13 Issue: 6
Author(s): Massimo Di Maio, Raffaele Costanzo, Pasqualina Giordano, Maria Carmela Piccirillo, Claudia Sandomenico, Agnese Montanino, Guido Carillio, Paolo Muto, David R. Jones, Gennaro Daniele, Francesco Perrone, Gaetano Rocco and Alessandro Morabito
Affiliation:
Keywords: Locally advanced NSCLC, multidisciplinary approach, combined treatment, chemotherapy, radiotherapy, surgery.
Abstract: Treatment of locally advanced non-small cell lung cancer (NSCLC) remains a significant challenge for oncologists, despite progress made in recent years in early diagnosis and therapy. This review focuses on integrated therapeutic approaches of patients with locally advanced NSCLC, summarizing the available evidence for patients with potentially resectable disease (stage IIIA-0/3) and with unresectable disease (stage IIIA-4/IIIB) and discussing several key questions related to the use of integrated approaches in NSCLC. Based on current evidence, neoadjuvant platinum-based combination chemotherapy is a treatment option in patients with potentially resectable stage IIIA-0/3: a 2-drug combination of platinum combined with a third-generation drug seems preferable, and at least 3 cycles of chemotherapy should be administered. There are no definitive evidences of clear superiority of surgery compared to radiotherapy for patients obtaining a response with neoadjuvant treatment: however, surgery is associated with a better local control, and subgroup analyses of randomized trials suggest improved outcome in patients in whom a complete resection could be obtained with a lobectomy, avoiding the increased surgical mortality associated with pneumonectomy. Standard treatment for patients with locally advanced, unresectable NSCLC is currently represented by combination of chemotherapy and radiotherapy. Concomitant approach has been proven superior to the sequential administration, although it is associated with higher risk of toxicity. All patients should be evaluated by a multidisciplinary team, skilled in multimodality treatment and should be counselled about risks and potential benefits of the different therapeutic approaches.
Export Options
About this article
Cite this article as:
Maio Di Massimo, Costanzo Raffaele, Giordano Pasqualina, Piccirillo Carmela Maria, Sandomenico Claudia, Montanino Agnese, Carillio Guido, Muto Paolo, Jones R. David, Daniele Gennaro, Perrone Francesco, Rocco Gaetano and Morabito Alessandro, Integrated Therapeutic Approaches in the Treatment of Locally Advanced Non-small Cell Lung Cancer, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (6) . https://dx.doi.org/10.2174/18715206113139990076
DOI https://dx.doi.org/10.2174/18715206113139990076 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lifestyle Interventions for Cardiovascular Risk Reduction in Women with Breast Cancer
Current Cardiology Reviews Targeted Therapy for Glioblastoma: Lessons Learned and Future Directions
Current Cancer Therapy Reviews Metal Complexes with Aromatic N-Containing Ligands as Potential Agents in Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Lung Cancer Mutations and Use of Targeted Agents in Hispanics
Reviews on Recent Clinical Trials PET/CT Based Dose Planning in Radiotherapy
Current Medical Imaging Nanotechnology and Antioxidant Therapy: An Emerging Approach for Neurodegenerative Diseases
Current Medicinal Chemistry Past, Present, and Future of Targeting Ras for Cancer Therapies
Mini-Reviews in Medicinal Chemistry Alkaloids and Flavonoids as α1-Adrenergic Receptor Antagonists
Current Medicinal Chemistry Virtual Screening of Anti-Cancer Compounds: Application of Monte Carlo Technique
Anti-Cancer Agents in Medicinal Chemistry Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Paclitaxel Efficacy is Increased by Parthenolide via Nuclear Factor- KappaB Pathways in In Vitro and In Vivo Human Non–Small Cell Lung Cancer Models
Current Cancer Drug Targets Design, Synthesis, Characterisation, and Evaluation of Substituted Quinolin-2-one Derivatives as Possible Anti-lung Cancer Agents
Current Drug Discovery Technologies ROS-Responsive Nanomedicine: Towards Targeting the Breast Tumor Microenvironment
Current Medicinal Chemistry A Novel Dual-labeled Peptide for Multimodal Imaging of EGFR with L858R Mutation
Current Radiopharmaceuticals Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Current Drug Targets Photoprotective Carotenoids Lutein and Zeaxanthin: Their Role in AMD
Current Nutrition & Food Science HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery LPTS: A Novel Tumor Suppressor Gene and a Promising Drug Target for Cancer Intervention
Recent Patents on Anti-Cancer Drug Discovery A Review of HPLC Methods Used for Determining the Presence of Meloxicam
Current Pharmaceutical Analysis